Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirella Lazarov

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 22, 2020
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 studyDaniel Morgensztern, Melissa Johnson, Charles M Rudin, et al.
The Journal of Investigative Dermatology|August 25, 2005
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis modelChristopher G De Vry, Marybeth Valdez, Mirella Lazarov, et al.
Inflammatory Bowel Diseases|July 27, 2005
RDP58 is a novel and potentially effective oral therapy for ulcerative colitisSimon Travis, Lee Min Yap, Chris Hawkey, et al.
Journal of Periodontology|May 1, 2010
Periodontal regeneration using an anabolic peptide with two carriers in baboonsMotofumi Yamashita, Mirella Lazarov, Archie A Jones, et al.
Nature Medicine|October 3, 2002
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesisMirella Lazarov, Yoshiaki Kubo, Ti Cai, et al.
Nature|February 7, 2003
NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaMaya Dajee, Mirella Lazarov, Jennifer Y Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Lung Cancer (Amsterdam, Netherlands)|May 22, 2020
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 studyDaniel Morgensztern, Melissa Johnson, Charles M Rudin, et al.
The Journal of Investigative Dermatology|August 25, 2005
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis modelChristopher G De Vry, Marybeth Valdez, Mirella Lazarov, et al.
Inflammatory Bowel Diseases|July 27, 2005
RDP58 is a novel and potentially effective oral therapy for ulcerative colitisSimon Travis, Lee Min Yap, Chris Hawkey, et al.
Journal of Periodontology|May 1, 2010
Periodontal regeneration using an anabolic peptide with two carriers in baboonsMotofumi Yamashita, Mirella Lazarov, Archie A Jones, et al.
Nature Medicine|October 3, 2002
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesisMirella Lazarov, Yoshiaki Kubo, Ti Cai, et al.
Nature|February 7, 2003
NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaMaya Dajee, Mirella Lazarov, Jennifer Y Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Pageof 1